Advances in Managing Acute Kidney Injury: Improving Outcomes for Patients Treated with High-Dose Methotrexate Case Study 2: HDMTX-Induced AKI in CNS Lymphoma
Case Study 2: HDMTX-Induced AKI in CNS Lymphoma
High-dose methotrexate (HDMTX) continues to be used in several treatment regimens for patients with solid tumors and hematologic malignancies. Despite appropriate supportive care measures during its administration, patients receiving HDMTX are at risk of developing acute kidney injury (AKI) due to delayed clearance. Advanced practice providers must understand the importance of having strategies in place to monitor patients treated with HDMTX for development of AKI, knowing the disease characteristics that trigger treatment with glucarpidase, and implementing best practices for treating HDMTX-induced AKI safely and effectively based on available evidence and guidelines.
Release date: September 10, 2019
Expiration date: September 10, 2020
Estimated time to complete: 0.5 hours
This activity is designed to help clinicians achieve specific learning objectives, which reflect the desired results of the education. Participants are encouraged to integrate what they learn from this activity into practice to improve patient care and outcomes.
Jointly provided by
Nancy Nix, PharmD, BCPS, BCOP, University of Georgia College of Pharmacy
Haleigh Mistry, MS, PA-C, University of Texas MD Anderson Cancer Center
This activity is designed for physician assistants (PAs), nurse practitioners (NPs), clinical nurse specialists (CNSs), and clinical oncology pharmacists (COPs), who provide care for patients treated with HDMTX.
- Plan strategies to monitor patients treated with HDMTX for development of AKI
- Identify patient and disease characteristics that trigger treatment with glucarpidase
- Formulate plans to treat AKI caused by HDMTX safely and effectively based on best available evidence and recent guidelines
This activity is certified for credit by Annenberg Center for Health Sciences at Eisenhower.
39000 Bob Hope Drive, Dinah Shore Building, Rancho Mirage, CA 92270
Voice: 760-773-4500; Fax: 760-773-4513; E-mail: email@example.com
© 2019, Annenberg Center for Health Sciences at Eisenhower. All rights reserved.
Statement of Credit
Participants who successfully complete this activity—which includes submitting a completed pre-test, submitting and scoring at least 70% on the post-test, and submitting a completed evaluation form—will be able to download a statement of credit.
To access the learning assessment and evaluation form, visit https://education.annenberg.net/5773-2
Accreditation and Designation Statements
Physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Harborside Medical Education. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses. Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 0.5 contact hours may be earned for successful completion of this activity.
Provider is approved by the California Board of Registered Nursing, Provider No. 13664, for 0.5 contact hours.
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity has been assigned ACPE Universal Program #0797-9999-19-095-H01-P. This activity is designated for up to 0.5 contact hours (0.05 CEUs) of continuing pharmacy education credit. This is a knowledge-based activity.
This activity is supported by educational grants from BTG International, Inc.
Relationships of Faculty and Planners
All individuals in a position to control the content of this activity (e.g., planners, faculty, reviewers) must disclose all financial relationships with commercial interests that may have a bearing on its subject matter. Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with its policies and procedures. Participants should assess the impact (if any) of the disclosed information on the educational value of the activity.
Nancy Nix, PharmD, BCPS, BCOP is on the speakers bureau for Coherus Biosciences and has been on the advisory boards for Bristol-Myers Squibb, Genentech, Puma, Sandoz, and Teva.
Haleigh Mistry, MS, PA-C, has nothing to disclose.
Planners and Reviewers
Activity reviewers and the staff of the Annenberg Center for Health Sciences at Eisenhower and Harborside Medical Education have nothing to disclose.
This activity may include discussion of agents that have not yet been approved by the U.S. Food and Drug Administration and investigational uses of approved products. Please consult prescribing information and practice guidelines for detail regarding safe and effective use of therapeutic agents.
The opinions expressed in this activity are those of the faculty and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any therapeutic agent or approach to diagnosis or patient management.
- 0.50 ACPE
- 0.50 AMA PRA Category 1 Credit(s)™
- 0.50 Attendance
- 0.50 CA-BRN
- 0.50 ANCC